Clinical Trial Update: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial of SHR-A1811 is ongoing as first-line treatment for advanced or metastatic non-small cell lung cancer with HER2 mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Non-Small Cell Lung Cancer With HER2- Mutations | Phase 3 | Status: RECRUITING